A5007497235- Bipolar Disorder and Treatment
- Schizophrenia research and treatment
- Electroconvulsive Therapy Studies
- Treatment of Major Depression
- Child and Adolescent Psychosocial and Emotional Development
- Mental Health and Psychiatry
- Epilepsy research and treatment
- Mental Health Research Topics
- Tryptophan and brain disorders
- Pharmacological Effects and Toxicity Studies
- Adolescent and Pediatric Healthcare
- Functional Brain Connectivity Studies
- Mental Health Treatment and Access
- Coordination Chemistry and Organometallics
- Electrolyte and hormonal disorders
- Stuttering Research and Treatment
- Attention Deficit Hyperactivity Disorder
- Psychosomatic Disorders and Their Treatments
- Health Systems, Economic Evaluations, Quality of Life
- Restless Legs Syndrome Research
- Suicide and Self-Harm Studies
- Diet and metabolism studies
- Advanced Neuroimaging Techniques and Applications
- Genetics and Neurodevelopmental Disorders
- Obsessive-Compulsive Spectrum Disorders
University of New Mexico
2016-2025
McLean Hospital
2009-2023
University of Pittsburgh
2023
University of California, San Francisco
2023
The University of Texas Health Science Center at San Antonio
2009-2021
Biomedical Development Corporation
2021
RELX Group (Netherlands)
2021
Stanford University
2004-2021
Emory University
2015-2021
VA Palo Alto Health Care System
2016-2021
Background: Despite the longer duration of depressive phase in bipolar disorder and frequent clinical use antidepressants combined with antipsychotics or mood stabilizers, relatively few controlled studies have examined treatment strategies for depression.Objective: To examine olanzapine olanzapine-fluoxetine combination I depression.Design: Double-blind, 8-week, randomized trial.Setting: Eighty-four sites (inpatient outpatient) 13 countries.Patients: A total 833 adults depression a...
The risk-benefit profile of antidepressant medications in bipolar disorder is controversial. When conclusive evidence lacking, expert consensus can guide treatment decisions. International Society for Bipolar Disorders (ISBD) convened a task force to seek recommendations on the use antidepressants disorders.An iteratively developed through serial consensus-based revisions using Delphi method. Initial survey items were based systematic review literature. Subsequent surveys included new or...
The primary intent of this study was to compare the efficacy and safety olanzapine placebo in treatment acute mania.The design involved a random-assignment, double-blind, placebo-controlled parallel group 3 weeks' duration. After 2- 4-day screening period, qualified patients were assigned either (N = 70) or 69). Patients began double-blind therapy with olanzapine, 10 mg, given once per day. first day treatment, daily dose could be adjusted upward downward, as clinically indicated, by one...
Objective: This study assessed the efficacy of olanzapine in delaying or preventing conversion to psychosis and reducing symptoms people with prodromal schizophrenia.Method: randomized trial occurred at four North American clinics Prevention Through Risk Identification, Management, Education project.Outpatients received (5-15 mg/day, N=31) placebo (N=29) during a 1-year double-blind treatment period no follow-up period.Efficacy measures included conversion-to-psychosis rate Scale Prodromal...
OBJECTIVE: Psychotic affective disorders are the most prevalent idiopathic psychoses, but their outcome from onset has rarely been studied. In this study, authors determined rate and latency of syndromal recovery rates functional after first lifetime hospitalization in patients with first-episode psychotic disorders. METHOD: From 1989–1996, 219 a DSM-IV illness were assessed at intervals over 24 months. Time to (no longer meeting episode criteria) was by survival analysis, (regaining...
Treatment-resistant depression is a significant public health concern; drug switching or augmentation often produce limited results. The authors hypothesized that fluoxetine could be augmented with olanzapine to successfully treat resistant depression.An 8-week double-blind study was conducted 28 patients who were diagnosed recurrent, nonbipolar, treatment-resistant without psychotic features. Subjects randomly assigned one of three groups: plus placebo, fluoxetine.Fluoxetine monotherapy...
Since improved prediction of illness course early in bipolar disorder is required to guide treatment planning, the authors evaluated recovery, first recurrence, and new onset following hospitalization for mania.Bipolar patients (N=166) were followed 2-4 years after their a manic or mixed episode assess timing predictors outcomes. Three aspects recovery measured: syndromal (DSM-IV criteria no longer met), symptomatic (Young Mania Rating Scale score </=5 Hamilton Depression </=8), functional...
<h3>Background</h3> A 6-week double-blind, randomized, placebo-controlled trial was conducted to determine the efficacy of combined therapy with olanzapine and either valproate or lithium compared alone in treating acute manic mixed bipolar episodes. <h3>Methods</h3> The primary objective evaluate (5-20 mg/d) vs placebo when added ongoing mood-stabilizer as measured by reductions Young Mania Rating Scale (YMRS) scores. Patients disorder (n = 344), episode, who were inadequately responsive...
OBJECTIVE: Few long-term studies have compared the efficacy and safety of typical atypical antipsychotic medications directly in patients with a first episode psychosis who met criteria for schizophrenia or related psychotic disorder. This study acute effectiveness haloperidol that olanzapine first-episode large, controlled clinical trial. METHOD: Patients (N=263) were randomly assigned under double-blind conditions to receive followed up 104 weeks. Domains measured included psychopathology,...
OBJECTIVE: The authors compared the efficacy of olanzapine and lithium in prevention mood episode relapse/recurrence. METHOD: Patients with a diagnosis bipolar disorder (manic/mixed), history two or more manic mixed episodes within 6 years, Young Mania Rating Scale total score ≥20 entered study received open-label cotreatment for 6–12 weeks. Those meeting symptomatic remission criteria (Young ≤12; 21-item Hamilton depression scale ≤8) were randomly assigned to 52 weeks double-blind...
In a placebo-controlled, double-blind study, the authors investigated efficacy and safety of olanzapine as monotherapy in relapse prevention bipolar I disorder.Patients achieving symptomatic remission from manic or mixed episode disorder (Young Mania Rating Scale [YMRS] total score < =12 21-item Hamilton Depression [HAM-D] <or =8) at two consecutive weekly visits following 6-12 weeks open-label acute treatment with 5-20 mg/day were randomly assigned to maintenance (N=225) placebo (N=136) for...
Abstract Objective To assess the efficacy, safety, and tolerability of cariprazine in treatment depressed phase bipolar I disorder adults ( NCT02670538 ). Methods In this 3 double‐blind placebo‐controlled study, adult patients with according to Diagnostic Statistical Manual — 5th Edition criteria a current depressive episode were randomized placebo (n = 167), 1.5 mg/day 168) or 3.0 158). Efficacy parameters changes Montgomery‐Åsberg Depression Rating Scale (MADRS) total scores (primary)...
OBJECTIVE: Few double-blind trials have compared longer-term efficacy and safety of medications for bipolar disorder. The authors report a 47-week comparison olanzapine divalproex. METHOD: This 47-week, randomized, study flexibly dosed (5–20 mg/day) to divalproex (500–2500 manic or mixed episodes disorder (N=251). only other psychoactive medication allowed was lorazepam agitation. primary instrument the Young Mania Rating Scale; priori protocol-defined threshold scores were ≥20 inclusion,...
Few controlled studies have examined the use of atypical antipsychotic drugs for prevention relapse in patients with bipolar I disorder. Aims To evaluate whether olanzapine plus either lithium or valproate reduces rate relapse, compared alone.Patients achieving syndromic remission after 6 weeks'treatment (0.6-1.2 mmol/l) (50-125 microg/ml) received 5-20 mg/day (combination therapy) placebo (monotherapy), and were followed a double-masked trial 18 months.The treatment difference time to into...
Objective:Magnetic resonance imaging (MRI) studies of schizophrenic patients have revealed structural brain abnormalities, with low volumes gray matter in the left posterior superior temporal gyrus and medial lobe structures. However, specificity to schizophrenia roles chronic morbidity neuroleptic treatment these abnormalities remain unclear. Method:Magnetic (1.5-T) scans were obtained from 33 first-episode psychosis 18 age-matched normal comparison subjects, all right-handed. Sixteen...
OBJECTIVE: The effect of antipsychotic medication on neurocognitive function remains controversial, especially since most previous work has compared the effects novel medications with those high doses conventional medications. This study compares olanzapine and low haloperidol in patients first-episode psychosis. METHOD: Patients a first episode schizophrenia, schizoaffective disorder, or schizophreniform disorder (N=167) were randomly assigned to double-blind treatment (mean modal dose=...
Objective: The purpose of this study was to evaluate the efficacy and safety olanzapine for treatment acute manic or mixed episodes associated with bipolar disorder in adolescents. Method: A 3-week multicenter, parallel, double-blind, randomized placebo-controlled trial conducted at 24 sites United States two Puerto Rico. participants were outpatient inpatient male female adolescents 13–17 years age an episode. Subjects received either (2.5–20 mg/day [N=107]) placebo (N=54). mean change from...